Xermelo
What Xermelo is used for
Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Xermelo
- Active substance
- telotristat ethyl
- Disease area
- Carcinoid Tumor; Neuroendocrine Tumors
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16A
- Marketing authorisation holder
- SERB SAS
- Authorised in the EU since
- 2017
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Xermelo used for?
Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.
What is the active substance in Xermelo?
Xermelo contains telotristat ethyl.
Who makes Xermelo?
The EU marketing authorisation holder is SERB SAS.
Is Xermelo an orphan medicine?
Yes. Xermelo is designated an orphan medicine in the EU, for a rare disease (Carcinoid Tumor; Neuroendocrine Tumors).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU